IPH6501 — Initial data
2026
Clinical data are expected to be presented in 2026.Source filing
catalyst calendar
INNATE PHARMA SA · Data as of 2026-10-25
2026
Clinical data are expected to be presented in 2026.Source filing
H2 2026
PACIFIC-9 Phase 3 readout for monalizumab, led by AstraZeneca, expected in H2 2026Source filing
Nov 18
Initial Phase 1 dose-escalation data will be presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) on November 18, 2026.Source filing